文献速递慢性静脉疾病

氰基丙烯酸酯闭合术治疗静脉性腿溃疡的12个月结果

Twelve-month results of cyanoacrylate closure in patients with venous leg ulceration.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-10-07

这项全球前瞻性单臂观察研究在17个中心纳入125例静脉性腿溃疡患者,评估VenaSeal氰基丙烯酸酯闭合系统联合标准伤口治疗的效果与安全性;12个月时溃疡愈合率81.3%、复发率17.0%,中位愈合时间92天,目标静脉解剖闭合率82.7%,并发症少且生活质量持续改善。

要点

  • 12个月溃疡愈合率81.3%,复发率17.0%,中位愈合时间92天。
  • 目标静脉解剖闭合成功率82.7%,不良事件包括肉芽肿、超敏反应和血栓性浅静脉炎。
  • 静脉特异性和通用生活质量评分较基线持续改善。

核心结论

  • VenaSeal可有效消除静脉性腿溃疡患者的大隐静脉反流,溃疡愈合率高、复发率低,并发症率低且生活质量改善。

研究设计与样本

  • 全球前瞻性单臂观察性研究,在美国和欧洲17个中心纳入125例静脉性腿溃疡患者,接受VenaSeal闭合系统联合标准伤口治疗(含多层压力治疗)。
  • 辅助治疗(静脉曲张、穿通静脉或溃疡下静脉丛)由治疗医生酌情决定。

主要发现

  • 12个月时溃疡愈合率为81.3%,溃疡复发率为17.0%。
  • 溃疡愈合中位时间为92天(95%CI 74-137)。
  • 所有目标静脉的解剖学闭合成功率为82.7%。
  • 临床事件委员会裁定的不良事件和严重不良事件包括:2例肉芽肿、1例超敏反应和4例治疗肢体血栓性浅静脉炎。
  • 静脉特异性和通用生活质量评分较基线持续改善。

关键数值与推荐

  • 12个月溃疡愈合率81.3%,复发率17.0%,中位愈合时间92天(95%CI 74-137)。
  • 目标静脉解剖闭合率82.7%。
  • 辅助泡沫硬化剂治疗应用于19.7%(31/157)的目标静脉。
  • 索引操作之外使用的医疗服务为每静脉年0.12次辅助治疗。

临床怎么用

  • 对于静脉性腿溃疡合并大隐静脉反流患者,可考虑使用VenaSeal氰基丙烯酸酯闭合系统联合标准伤口治疗以促进溃疡愈合和降低复发。
  • 治疗决策中需权衡不良事件风险,包括肉芽肿、超敏反应和血栓性浅静脉炎。

局限性

  • 本研究为单臂观察性研究,无对照组,无法与其它静脉消融方式直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous leg ulceration (VLU) is a major cause of patient distress and health care burden. Previous studies have highlighted the importance of early endovenous ablation of superficial venous reflux to expedite healing and prevent recurrence, but the optimal venous ablation modality is unclear. OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety of cyanoacrylate closure in patients with VLU. DESIGN: A global, prospective, single-arm observational study was conducted in 17 centers across the United States and Europe. A total of 125 participants with VLU were included and treated with the VenaSeal closure system (Medtronic), in addition to standard wound therapy, including multilayered compression. Adjuvant treatments to varicosities, perforators or the subulcer plexus were left to the discretion of treating clinicians. The primary outcome was VLU healing through 12 months. Secondary outcomes included time to ulcer recurrence, anatomic vein closure, target limb adverse events (AEs), and changes in quality-of-life (QoL) measures. RESULTS: One hundred twenty-five participants with VLU and saphenous vein reflux were enrolled. The mean ±standard deviation age was 67.9 ± 14.76 years, with 38.4% females and an overall mean body mass index of 32.4 ± 9.35. Concomitant foam sclerotherapy treatments were performed in 19.7% (31/157) of target veins. At 12 months, ulcer healing was 81.3%, and ulcer recurrence was 17.0%. The median time to ulcer healing was 92 days (95% confidence interval, 74-137). Anatomic vein closure was successful in 82.7% of all target veins. clinical events committee-adjudicated AE and serious AEs included: two granulomas, one hypersensitivity reaction, and four cases of phlebitis of the treated limb. Health care services used outside the index procedure yielded 0.12 adjunctive therapies per vein-year. Venous-specific and generic QoL scores showed sustained improvement compared with baseline scores. CONCLUSIONS: VenaSeal effectively eliminated saphenous reflux in patients with VLU. The ulcer healing rate was high, and the recurrence rate was low. Complication rates were also low and QoL improved.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Gibson K, Gohel M, Kayssi A, et al. Twelve-month results of cyanoacrylate closure in patients with venous leg ulceration. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42843552. doi:10.1016/j.jvsv.2026.102635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。